



manufacture of a medicament, for treating a subject suffering from a disease or condition associated with aberrant activity of a CDK, wherein the disease or condition is selected from the group consisting of cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, autoimmune disease, and an infectious disease.

In an embodiment, there is provided the use of the composition as disclosed herein in the manufacture of a medicament, for treating a disease or condition selected from cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, autoimmune disease, or an infectious disease.

In a further aspect, there is provided a compound selected from any one of the compounds set forth below:





6. A pharmaceutical composition comprising a compound of any one of claims 1-5 and a pharmaceutically acceptable excipient.
7. Use of the composition of claim 6 in the manufacture of a medicament, for treating a subject suffering from a disease or condition associated with aberrant activity of a CDK, wherein the disease or condition is selected from the group consisting of cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, autoimmune disease, and an infectious disease.
8. The use of claim 7, wherein the disease or condition is suffered by a human subject.
9. The use of any one of claims 7-8, wherein the disease is cancer.
10. The use of claim 9, wherein the cancer is selected from the group consisting of a blood cancer, melanoma, a bone cancer, a breast cancer, a brain cancer, and a lung cancer.
11. The use of claim 10, wherein the cancer is a blood cancer selected from chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), T-cell acute lymphoblastic leukemia (T-ALL), chronic myelogenous leukemia (CML), acute

myelogenous leukemia (AML), lymphoma, and multiple myeloma.

12. The use of claim 10, wherein the cancer is selected from osteosarcoma, Ewing's sarcoma, triple-negative breast cancer (TNBC), neuroblastoma, and small cell lung cancer (SCLC).

13. The use of any one of claims 7-12, wherein the composition is to be used in conjunction with one or more additional agents independently selected from anti-proliferative agents, anti-cancer agents, immunosuppressant agents, and pain-relieving agents.

14. A compound selected from any one of the compounds set forth below:

